Ovarian superstimulation and in vivo embryo production using a short or long-term progesterone treatment and different porcine FSH presentations in acyclic Toggenburg goats

在无周期托根堡山羊中,采用短期或长期孕酮治疗和不同猪促卵泡激素(FSH)剂量进行卵巢超刺激和体内胚胎生产

阅读:1

Abstract

This 2 × 2 factorial study evaluated different progesterone treatment durations and porcine follicle-stimulating hormone (pFSH) presentations for superovulation in acyclic Toggenburg goats. Goats (n = 56) received short (six days, G6) and long-term (17 days, G17) progesterone intravaginal devices combined with 133 mg (G6(133mg) and G17(133mg)) or 250 IU of pFSH (G6(250IU) and G17(250IU)) administered in six decreasing doses from 48 h before to 12 h after device removal. Does were naturally mated while in estrus. To monitor ovulation and the number of corpora lutea, ovarian transrectal ultrasound evaluations were performed on the days of the first pFSH administration, device removal, and six days later. Non-surgical embryo recovery (NSER) was performed 6–7 days after the first breeding. The G6(250IU) group had a shorter estrus duration and required fewer matings than the other groups (P < 0.05). Overall, the interval between the last dose of pFSH and the first sign of estrus detected (46.2 ± 2.3 vs. 35.3 ± 2.5 h) and the duration of estrus (38.2 ± 1.9 vs. 31.3 ± 3 h) differed (P < 0.05) between FSH(133mg) and FSH(250IU), respectively, regardless of progesterone treatment duration. Shorter duration of NSER proceeding and higher embryo viability rate (P < 0.05) were observed in G17 groups. However, the percentage of viable structures was higher (P < 0.05) in G6(133mg) (52.5%; 21/40) and G17(250IU) (54.5%; 30/55) groups than in the G6(250IU) (10.6%; 5/47) and G17(133mg) (23.3%; 7/30) groups. In conclusion, short-term treatment with 133 mg of pFSH is effective in achieving satisfactory embryo viability rate while minimizing the animal’s exposure to progesterone.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。